PT  - JOURNAL ARTICLE
AU  - Elmunzer, B. Joseph
AU  - Spitzer, Rebecca L.
AU  - Foster, Lydia D.
AU  - Merchant, Ambreen A.
AU  - Howard, Eric F.
AU  - Patel, Vaishali A.
AU  - West, Mary K.
AU  - Qayed, Emad
AU  - Nustas, Rosemary
AU  - Zakaria, Ali
AU  - Piper, Marc S.
AU  - Taylor, Jason R.
AU  - Jaza, Lujain
AU  - Forbes, Nauzer
AU  - Chau, Millie
AU  - Lara, Luis F.
AU  - Papachristou, Georgios I.
AU  - Volk, Michael L.
AU  - Hilson, Liam G.
AU  - Zhou, Selena
AU  - Kushnir, Vladimir M.
AU  - Lenyo, Alexandria M.
AU  - McLeod, Caroline G.
AU  - Amin, Sunil
AU  - Kuftinec, Gabriela N.
AU  - Yadav, Dhiraj
AU  - Fox, Charlie
AU  - Kolb, Jennifer M.
AU  - Pawa, Swati
AU  - Pawa, Rishi
AU  - Canakis, Andrew
AU  - Huang, Christopher
AU  - Jamil, Laith H.
AU  - Aneese, Andrew M.
AU  - Glamour, Benita K.
AU  - Smith, Zachary L
AU  - Hanley, Katherine A.
AU  - Wood, Jordan
AU  - Patel, Harsh K.
AU  - Shah, Janak N.
AU  - Agarunov, Emil
AU  - Sethi, Amrita
AU  - Fogel, Evan L.
AU  - McNulty, Gail
AU  - Haseeb, Abdul
AU  - Trieu, Judy A.
AU  - Dixon, Rebekah E.
AU  - Yang, Jeong Yun
AU  - Mendelsohn, Robin B.
AU  - Calo, Delia
AU  - Aroniadis, Olga C.
AU  - LaComb, Joseph F.
AU  - Scheiman, James M.
AU  - Sauer, Bryan G.
AU  - Dang, Duyen T.
AU  - Piraka, Cyrus R.
AU  - Shah, Eric D.
AU  - Pohl, Heiko
AU  - Tierney, William M.
AU  - Mitchell, Stephanie
AU  - Condon, Ashwinee
AU  - Lenhart, Adrienne
AU  - Dua, Kulwinder S.
AU  - Kanagala, Vikram S.
AU  - Kamal, Ayesha
AU  - Singh, Vikesh K.
AU  - Pinto-Sanchez, Maria Ines
AU  - Hutchinson, Joy M.
AU  - Kwon, Richard S.
AU  - Korsnes, Sheryl J.
AU  - Singh, Harminder
AU  - Solati, Zahra
AU  - Deshpande, Amar R.
AU  - Rockey, Don C.
AU  - Alford, Teldon B.
AU  - Durkalski, Valerie
AU  - ,
TI  - Digestive Manifestations in Patients Hospitalized with COVID-19
AID  - 10.1101/2020.07.07.20143024
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.07.20143024
4099  - http://medrxiv.org/content/early/2020/08/11/2020.07.07.20143024.short
4100  - http://medrxiv.org/content/early/2020/08/11/2020.07.07.20143024.full
AB  - Background The prevalence and significance of digestive manifestations in COVID-19 remain uncertain.Methods Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.Results A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death.Conclusions Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical courseCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThis was an observational studyFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval was obtained at each center prior to patient identification and data collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors had access the data